放射治疗与免疫治疗之间的关系
The Relationship between Radiation Therapy and Immunotherapy
DOI: 10.12677/ACM.2022.122148, PDF,    科研立项经费支持
作者: 刘根利：大连医科大学规培医院青岛市市立医院，山东 青岛；鲁永织, 陶风英, 李 玲, 杨 雪, 王笑荷, 袁胜利*：青岛市市立医院肿瘤二科，山东 青岛
关键词: 放射治疗；免疫治疗；远隔效应；Radiotherapy； Immunotherapy； Abscopal Effect
摘要: 放射治疗是诊断后一半以上癌症患者的主要抗癌方式，与化学疗法相比，其具有局部肿瘤控制的优势，且系统性副作用相对较少。然而，放射治疗的疗效受到获得性肿瘤耐药性的限制，导致复发和转移的风险。自从免疫疗法在癌症治疗中出现以来，现在已经确定放疗与此类治疗的关联可以促进放射诱导的抗肿瘤免疫的出现。因此，这种组合近年来引起了科学界越来越大的兴趣，并正在大量临床前模型中进行研究，也在许多临床试验中付诸实践。在这篇综述中，我们旨在总结放射治疗与免疫系统之间的相互影响以及放射治疗与免疫治疗相结合对肿瘤治疗效果的影响。
Abstract: Radiation therapy is the main anti-cancer method for more than half of the cancer patients after diagnosis, it has the advantage of local tumor control over chemotherapy and has relatively few systemic side effects. However, the efficacy of radiotherapy is limited by resistance to acquired tumors, leading to the risk of recurrence and metastasis. Since the advent of immunotherapy in cancer therapy, it has now been established that the association of radiation therapy with such treatments can promote the emergence of radiation-induced antitumor immunity. Therefore, this combination has attracted increasing interest in the scientific community in recent years and is being studied in a large number of preclinical models and also put into practice in many clinical trials. In this review, we aimed to summarize the inter effects between radiotherapy and the immune system and the impact of the combination of radiotherapy and immunotherapy on the effect of tumor therapy.
文章引用：刘根利, 鲁永织, 陶风英, 李玲, 杨雪, 王笑荷, 袁胜利. 放射治疗与免疫治疗之间的关系[J]. 临床医学进展, 2022, 12(2): 1014-1021. https://doi.org/10.12677/ACM.2022.122148

参考文献

[1] Orth, M., Lauber, K., Niyazi, M., Friedl, A.A., Li, M., Maihöfer, C., et al. (2014) Current Concepts in Clinical Radiation Oncology. Radiation and Environmental Biophysics, 53, 1-29. [Google Scholar] [CrossRef] [PubMed]
[2] Baumann, M., Krause, M., Overgaard, J., Debus, J., Bentzen, S.M., Daartz, J., et al. (2016) Radiation Oncology in the Era of Precision Medicine. Nature Reviews Cancer, 16, 234-249. [Google Scholar] [CrossRef] [PubMed]
[3] Thomas, L. (1959) Cellular and Humoral Aspects of the Hypersensitive States: A Symposium Held at the New York Academy of Medicine. Hoeber-Harper, New York.
[4] Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. and Schreiber, R.D. (2002) Cancer Immunoediting: From Immunosurveillance to Tumor Escape. Nature Immunology, 3, 991-998.
[5] Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity, 21, 137-148. [Google Scholar] [CrossRef] [PubMed]
[6] Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360.
[7] Vesely, M.D., Kershaw, M.H., Schreiber, R.D. and Smyth, M.J. (2011) Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 29, 235-271.
[8] Jiang, W., Chan, C.K., Weissman, I.L., Kim, B.Y.S. and Hahn, S.M. (2016) Immune Priming of the Tumor Microenvironment by Radiation. Trends in Cancer, 2, 638-645. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, J.Y., Son, Y.O., Park, S.W., Bae, J.H., Chung, J.S., Kim, H.H., et al. (2006) Increase of NKG2D Ligands and Sensitivity to NK Cell-Mediated Cytotoxicity of Tumor Cells by Heat Shock and Ionizing Radiation. Experimental & Molecular Medicine, 38, 474-484.
[10] Chakraborty, M., Abrams, S.I., Camphausen, K., Liu, K., Scott, T., Coleman, C.N., et al. (2003) Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy. The Journal of Immunology, 170, 6338-6347.
[11] Filatenkov, A., Baker, J., Mueller, A.M., Kenkel, J., Ahn, G.O., Dutt, S., et al. (2015) Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21, 3727-3739. [Google Scholar] [CrossRef] 
[12] Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., et al. (2013) Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy. Cancer Cell, 24, 589-602. [Google Scholar] [CrossRef] [PubMed]
[13] Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W. and Lin, S.H. (2018) Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Frontiers in Pharmacology, 9, Article No. 185. [Google Scholar] [CrossRef] [PubMed]
[14] Thomas, D.A. and Massague, J. (2005) TGF-β Directly Targets Cytotoxic T Cell Functions during Tumor Evasion of Immune Surveillance. Cancer Cell, 8, 369-380. [Google Scholar] [CrossRef] [PubMed]
[15] Gorelik, L. and Flavell, R.A. (2001) Immune-Mediated Eradication of Tumors through the Blockade of Transforming Growth Factor-Beta Signaling in T Cells. Nature Medicine, 7, 1118-1122. [Google Scholar] [CrossRef] [PubMed]
[16] Heeran, A.B., Berrigan, H.P. and O’Sullivan, J. (2019) The Radiation-Induced Bystander Effect (RIBE) and Its Connections with the Hallmarks of Cancer. Radiation Research, 192, 668-679. [Google Scholar] [CrossRef] 
[17] Turgeon, G.A., Weickhardt, A., Azad, A.A., Solomon, B. and Siva, S. (2019) Radiotherapy and Immunotherapy: A Synergistic Effect in Cancer Care. Medical Journal of Australia, 210, 47-53. [Google Scholar] [CrossRef] [PubMed]
[18] Krombach, J., Hennel, R., Brix, N., Orth, M., Schoetz, U., Ernst, A., Schuster, J., Zuchtriegel, G., Reichel, C.A. and Bierschenk, S. (2019) Priming Anti-Tumor Immunity by Radiotherapy: Dying Tumor Cell-Derived DAMPs Trigger Endothelial Cell Activation and Recruitment of Myeloid Cells. OncoImmunology, 8, e1523097. [Google Scholar] [CrossRef] 
[19] McLaughlin, M., Patin, E.C., Pedersen, M., Wilkins, A., Dillon, M.T., Melcher, A.A. and Harrington, K.J. (2020) Inflammatory Microenvironment Remodelling by Tumour Cells after Radiotherapy. Nature Reviews Cancer, 20, 203-217. [Google Scholar] [CrossRef] [PubMed]
[20] Mehla, K. and Singh, P.K. (2019) Metabolic Regulation of Macrophage Polarization in Cancer. Trends in Cancer, 5, 822-834. [Google Scholar] [CrossRef] [PubMed]
[21] Yang, X., Guo, Y., Guo, Z., Si, T., Xing, W., Yu, W. and Wang, Y. (2019) Cryoablation Inhibition of Distant Untreated Tumors (Abscopal Effect) Is Immune Mediated. Oncotarget, 10, 4180-4191. [Google Scholar] [CrossRef] [PubMed]
[22] Reynders, K., Illidge, T., Siva, S., Chang, J.Y. and De Ruysscher, D. (2015) The Abscopal Effect of Local Radiotherapy: Using Immunotherapy to Make a Rare Event Clinically Relevant. Cancer Treatment Reviews, 41, 503-510.
[23] Hu, Z.I., McArthur, H.L. and Ho, A.Y. (2017) The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Current Breast Cancer Reports, 9, 45-51. [Google Scholar] [CrossRef] [PubMed]
[24] Sun, Z., Chen, F., Meng, F., Wei, J. and Liu, B. (2017) MHC Class II Restricted Neoantigen: A Promising Target in Tumor Immunotherapy. Cancer Letters, 392, 17-25. [Google Scholar] [CrossRef] [PubMed]
[25] Sethuraman, S.N. and Ranjan, A. (2016) Neoantigen Activation, Protein Translocation and Targeted Drug Delivery in Combination with Radiotherapy. Therapeutic Delivery, 7, 377-385. [Google Scholar] [CrossRef] [PubMed]
[26] Marconi, R., Strolin, S., Bossi, G. and Strigari, L. (2017) A Meta-Analysis of the Abscopal Effect in Preclinical Models: Is the Biologically Effective Dose a Relevant Physical Trigger? PLoS ONE, 12, e0171559. [Google Scholar] [CrossRef] [PubMed]
[27] Johnson, C.B. and Jagsi, R. (2016) The Promise of the Abscopal Effect and the Future of Trials Combining Immunotherapy and Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, 95, 1254-1256.
[28] Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377. [Google Scholar] [CrossRef] [PubMed]
[29] Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., et al. (2006) Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy. Journal of Experimental Medicine, 203, 1259-1271. [Google Scholar] [CrossRef] [PubMed]
[30] Sato, H., Niimi, A., Yasuhara, T., Permata, T.B.M., Hagiwara, Y., Isono, M., et al. (2017) DNA Double-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells. Nature Communications, 8, Article No. 1751. [Google Scholar] [CrossRef] [PubMed]
[31] Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. (2014) Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients. Nature, 515, 563-567. [Google Scholar] [CrossRef] [PubMed]
[32] Sharabi, A.B., Lim, M., DeWeese, T.L. and Drake, C.G. (2015) Radiation and Checkpoint Blockade Immunotherapy: Radiosensitisation and Potential Mechanisms of Synergy. The Lancet Oncology, 16, E498-E509. [Google Scholar] [CrossRef] 
[33] Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., et al. (2018) Increased Vessel Perfusion Predicts the Efficacy of Immune Checkpoint Blockade. The Journal of Clinical Investigation, 128, 2104-2115.
[34] O’Donnell, J.S., Teng, M.W.L. and Smyth, M.J. (2019) Cancer Immunoediting and Resistance to T Cell-Based Immunotherapy. Nature Reviews Clinical Oncology, 16, 151-167. [Google Scholar] [CrossRef] [PubMed]
[35] Ozpiskin, O.M., Zhang, L. and Li, J.J. (2019) Immune Targets in the Tumor Microenvironment Treated by Radiotherapy. Theranostics, 9, 1215-1231. [Google Scholar] [CrossRef] [PubMed]
[36] Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H. and Yu, J. (2018) Abscopal Effect of Radiotherapy Combined with Immune Checkpoint Inhibitors. Journal of Hematology & Oncology, 11, Article No. 104. [Google Scholar] [CrossRef] [PubMed]
[37] Levy, A., Chargari, C., Marabelle, A., Perfettini, J.L., Magné, N. and Deutsch, E. (2016) Can Immunostimulatory Agents Enhance the Abscopal Effect of Radiotherapy? European Journal of Cancer, 62, 36-45.
[38] Shaverdian, N., Lisberg, A.E., Bornazyan, K., et al. (2017) Previous Radiotherapy and the Clinical Activity and Toxicity of Pembrolizumab in the Treatment of Non-Small-Cell Lung Cancer: A Secondary Analysis of the KEYNOTE-001 Phase 1 Trial. The Lancet Oncology, 18, 895-903. [Google Scholar] [CrossRef] 
[39] Maity, A., Mick, R., Huang, A.C., et al. (2018) A Phase I Trial of Pembrolizumab with Hypofractionated Radiotherapy in Patients with Metastatic Solid Tumours. British Journal of Cancer, 119, 1200-1207. [Google Scholar] [CrossRef] [PubMed]
[40] Young, K.H., Baird, J.R., Savage, T., Cottam, B., Friedman, D., Bambina, S., et al. (2016) Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS ONE, 11, e0157164. [Google Scholar] [CrossRef] [PubMed]
[41] Antonia, S.J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., et al. (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 377, 1919-1929.
[42] Lee, Y., Auh, S.L., Wang, Y., Burnette, B., Wang, Y., Meng, Y., et al. (2009) Therapeutic Effects of Ablative Radiation on Local Tumor Require CD8+ T Cells: Changing Strategies for Cancer Treatment. Blood, 114, 589-595. [Google Scholar] [CrossRef] [PubMed]
[43] Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G. and Lord, E.M. (2005) Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells that Traffic to the Tumor. The Journal of Immunology, 174, 7516-7523. [Google Scholar] [CrossRef] [PubMed]
[44] Kim, M.S., Kim, W., Park, I.H., Kim, H.J., Lee, E., Jung, J.H., et al. (2015) Radiobiological Mechanisms of Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery. Radiation Oncology Journal, 33, 265-275. [Google Scholar] [CrossRef] [PubMed]
[45] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England Journal of Medicine, 372, 2509-2520.
[46] Khagi, Y., Goodman, A.M., Daniels, G.A., Patel, S.P., Sacco, A.G., Randall, J.M., et al. (2017) Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23, 5729-5736. [Google Scholar] [CrossRef] 
[47] Gopalakrishnan, V., Spencer, C.N., Nezi, L., Reuben, A., Andrews, M.C., Karpinets, T.V., et al. (2018) Gut Microbiome Modulates Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Science, 359, 97-103.

为你推荐